BRIEF—Helsinn and Angelini Pharma renew distribution deal

Helsinn and Angelini Pharma have renewed their distribution and licence agreement for Aulin (nimesulide) and Mesulid (nimesulide).

The deal covers Bulgaria, Slovakia, Czech Republic, Hungary, Poland and Romania.

The products are NSAIDs prescribed as oral tablets or granules for oral suspension, used as second-line treatments for acute pain and primary dysmenorrhea.

Erik Lommerde, Angelini’s executive VP for international operations, said the alliance was: “crucial for both parties and represents a strong business relationship.”